<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2198">
  <stage>Registered</stage>
  <submitdate>1/12/2008</submitdate>
  <approvaldate>1/12/2008</approvaldate>
  <nctid>NCT00800683</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive</studytitle>
    <scientifictitle>Safety in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 vs. Placebo, DB, Parallel Group, Randomized, Insulin Background Inclusive</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2008-001569-27</secondaryid>
    <secondaryid>1218.43</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BI 1356
Treatment: drugs - placebo

Experimental: BI 1356 - patient to receive a tablet containing BI 1356 once daily

Placebo Comparator: placebo - patient to receive a tablet identical to BI 1356 once daily


Treatment: drugs: BI 1356
BI 1356 dosed once daily

Treatment: drugs: placebo
placebo matching BI 1356 taken once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HbA1c Change From Baseline at Week 12 - HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline continuous HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c Change From Baseline at Week 52 - HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 52 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.</outcome>
      <timepoint>Baseline and Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c Change From Baseline at Week 18 - HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.</outcome>
      <timepoint>Baseline and Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c Change From Baseline at Week 24 - HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.</outcome>
      <timepoint>Baseline and Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c Change From Baseline at Week 30 - HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.</outcome>
      <timepoint>Baseline and Week 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c Change From Baseline at Week 36 - HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 36 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.</outcome>
      <timepoint>Baseline and Week 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c Change From Baseline at Week 42 - HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 42 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.</outcome>
      <timepoint>Baseline and Week 42</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c Change From Baseline at Week 48 - HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 48 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.</outcome>
      <timepoint>Baseline and Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of &lt;6.5% After 52 Weeks of Treatment - The percentage of patients with an HbA1c value below 6.5% at week 52 was calculated for each treatment arm. Non-completers were imputed as failure (NCF). Analysis was only performed on patients with baseline HbA1c&gt;=6.5%</outcome>
      <timepoint>Baseline and Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Occurrence of a Treat to Target Efficacy Response, That is an HbA1c Under Treatment of &lt;7.0% After 52 Weeks of Treatment - The percentage of patients with an HbA1c value below 7.0% at week 52 was calculated for each treatment arm. Non-completers were imputed as failure (NCF). Analysis was only performed on patients with baseline HbA1c&gt;=7%.</outcome>
      <timepoint>Baseline and Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Patients With HbA1c Lowering by 0.5% at Week 52 - The percentage of patients with an HbA1c reduction from baseline &gt;=0.5% at week 52 was calculated for each treatment arm. Non-completers were imputed as failure (NCF).</outcome>
      <timepoint>Baseline and Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FPG Change From Baseline at Week 12 - This change from baseline reflects the week 12 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , creatinine clearance , HbA1c and background of anti diabetic drugs</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FPG Change From Baseline at Week 18 - Model includes treatment, continuous baseline FPG , creatinine clearance , HbA1c and background of anti diabetic drugs</outcome>
      <timepoint>Baseline and Week 18</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FPG Change From Baseline at Week 24 - This change from baseline reflects the week 24 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs</outcome>
      <timepoint>Baseline and Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FPG Change From Baseline at Week 30 - This change from baseline reflects the week 30 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs</outcome>
      <timepoint>Baseline and Week 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FPG Change From Baseline at Week 36 - This change from baseline reflects the week 36 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs</outcome>
      <timepoint>Baseline and Week 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FPG Change From Baseline at Week 42 - This change from baseline reflects the week 42 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs</outcome>
      <timepoint>Baseline and Week 42</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FPG Change From Baseline at Week 48 - This change from baseline reflects the week 48 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs</outcome>
      <timepoint>Baseline and Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>FPG Change From Baseline at week52 - This change from baseline reflects the week 52 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs</outcome>
      <timepoint>Baseline and Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Antidiabetic Background Therapy Dose at 52 Weeks Compared to Baseline and Over Time - Number of patients with at least one change in daily dose, determined by at least a 10% increase in insulin.</outcome>
      <timepoint>Baseline and Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically Relevant Drug-related Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG - Clinically relevant drug-related abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as adverse events.</outcome>
      <timepoint>first administration of randomised treatment to ....</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Male and female patients with type 2 diabetes and with glomerular filtration rate
             (GFR) &lt;30 ml/min, who are not on chronic dialysis.

          -  Insufficient glycemic control (hemoglobin A1c (HbA1c) between 7.0% and 10.0%)

          -  Age 18 or over and not older than 80 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Treatment with any other anti diabetic drug other than insulin and/or sulphonylurea
             within 3 months prior to informed consent

          -  Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior
             to informed consent

          -  Unstable or acute congestive heart failure</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>133</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>1218.43.61009 Boehringer Ingelheim Investigational Site - Gosford</hospital>
    <hospital>1218.43.61010 Boehringer Ingelheim Investigational Site - Auchenflower</hospital>
    <hospital>1218.43.61006 Boehringer Ingelheim Investigational Site - Kippa Ring</hospital>
    <hospital>1218.43.61007 Boehringer Ingelheim Investigational Site - Reservoir</hospital>
    <hospital>1218.43.61011 Boehringer Ingelheim Investigational Site - Richmond</hospital>
    <hospital>1218.43.61005 Boehringer Ingelheim Investigational Site - Adelaide, SA</hospital>
    <hospital>1218.43.61002 Boehringer Ingelheim Investigational Site - Herston, QLD</hospital>
    <postcode> - Gosford</postcode>
    <postcode> - Auchenflower</postcode>
    <postcode> - Kippa Ring</postcode>
    <postcode> - Reservoir</postcode>
    <postcode> - Richmond</postcode>
    <postcode> - Adelaide, SA</postcode>
    <postcode> - Herston, QLD</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>New Territories</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Afula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Nahariya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Safed</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Takpuna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lugansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Ternopil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Zaporizhzhya</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>to determine safety, efficacy and tolerability of BI 1356 versus placebo</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00800683</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>